Literature DB >> 10604946

Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice.

M Yamano1, H Yuki, S Yasuda, K Miyata.   

Abstract

Depression-like behavior induced by YM643, a consensus interferon-alpha (IFN-alpha), was evaluated with the tail-suspension test in mice and compared with depression-like behavior induced by sumiferon, a natural IFN-alpha. To investigate the mechanism of IFN-alpha-induced depression-like behavior, the effects of the tricyclic antidepressant imipramine, the cyclooxygenase inhibitor indomethacin, the opioid receptor antagonist naloxone, and the selective corticotropin-releasing hormone receptor antagonist CP-154, 526 on IFN-alpha-induced depression-like behavior were evaluated. Intravenously injected YM643 (2 x 10(8)-2 x 10(9) U/kg) and sumiferon (2 x 10(6)-2 x 10(7) I.U./kg) dose-dependently increased immobility time. Repeated s.c. injection of either YM643 (6 x 10(6)-6 x 10(8) U/kg) or sumiferon (6 x 10(4)-6 x 10(6) I.U./kg) for 7 days also dose-dependently increased immobility time. After i.c.v. injection of either YM643 (2 x 10(6) U/mouse) or sumiferon (6 x 10(4) I.U./mouse), significant prolongation of immobility time also was observed. Pretreatment with imipramine (30 mg/kg s.c.) significantly reduced the YM643- or sumiferon-induced increases in immobility time. CP-154,526 (0.3-3 mg/kg s.c.) dose-dependently reduced YM643- or sumiferon-induced increases in immobility time with ID(50) values of 0.6 mg/kg against YM643 and 1.3 mg/kg against sumiferon. However, neither indomethacin (10 mg/kg s.c.) nor naloxone (3 mg/kg s.c.) had any effect on YM643- or sumiferon-induced increases in immobility time. These results suggest that IFN-alpha centrally induces depression-like behavior in mice that can be alleviated with imipramine. The results also suggest that activation of corticotropin-releasing hormone receptors is involved in IFN-alpha-induced depression-like behavior, but the prostaglandin and opioid systems do not participate in this process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604946

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

Review 2.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

Review 3.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

Review 4.  Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.

Authors:  Glenn R Valdez
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  Progress in corticotropin-releasing factor-1 antagonist development.

Authors:  Eric P Zorrilla; George F Koob
Journal:  Drug Discov Today       Date:  2010-03-03       Impact factor: 7.851

6.  Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?

Authors:  Y Taché
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

7.  Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior.

Authors:  François Frenois; Maïté Moreau; Jason O'Connor; Marc Lawson; Charlotte Micon; Jacques Lestage; Keith W Kelley; Robert Dantzer; Nathalie Castanon
Journal:  Psychoneuroendocrinology       Date:  2007-05-04       Impact factor: 4.905

8.  Decreased immobility in swimming test by homologous interferon-alpha in mice accompanied with increased cerebral tryptophan level and serotonin turnover.

Authors:  Jianping Wang; Adrian J Dunn; Amanda J Roberts; Hua Zhang
Journal:  Neurosci Lett       Date:  2009-01-24       Impact factor: 3.046

9.  Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm.

Authors:  Georgina Valeria Fernández Macedo; María Laura Cladouchos; Laura Sifonios; Pablo Martín Cassanelli; Silvia Wikinski
Journal:  Psychopharmacology (Berl)       Date:  2012-09-08       Impact factor: 4.530

10.  Development of a murine animal model of depression for repeated dosing with human interferon alpha.

Authors:  Nagesh Koregala Siddegowda; N Sanjay Kumar Rao; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2011-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.